anti-MUC1 IgE

**anti-MUC1 IgE** is a mouse/human chimeric immunoglobulin E (IgE) monoclonal antibody targeting the human MUC1 antigen, a transmembrane mucin overexpressed and aberrantly glycosylated on many solid tumors including pancreatic ductal adenocarcinoma (PDAC), breast cancer, and others. It binds specifically to the PDTRPAP sequence in the MUC1 tandem repeat domain, engaging FcεRI receptors on effector cells such as mast cells, eosinophils, natural killer (NK) cells, and dendritic cells to mediate antibody-dependent cellular cytotoxicity (ADCC), tumor cell lysis, and antigen cross-presentation to CD8 T cells. Preclinical studies in hMUC1/hFcεRIα double transgenic mice demonstrate robust anti-tumor efficacy against subcutaneous and orthotopic PDAC models when combined with anti-PD-L1 checkpoint inhibitor and TLR3 agonist PolyICLC, promoting NK- and CD8 T-cell dependent tumor rejection, survival improvement, and persistent MUC1-specific immunity without inducing anaphylaxis at tested doses. Developed using technology licensed from UCLA, Stanford, and Advanced Immune Therapeutics by OncoQuest, it represents an investigational IgE-based immunotherapy shifting from traditional IgG approaches to harness allergic effector mechanisms against immunosuppressive tumors.

Other names

mouse/human chimeric anti-MUC1 IgE1F5.hIgE